Bloomage Biotech(SH:688363) Feng Huang Wang Cai Jing·2025-08-10 09:54Core Viewpoint - Huaxi Biological is facing serious allegations of financial misconduct, including accusations of financial fraud and inflated revenue figures, as detailed by a former employee who claims to have evidence supporting these claims [1][2][4]. Financial Allegations - The controlling shareholder, Huaxi Xinyu Investment Co., holds 283.5 million shares of Huaxi Biological, representing 58.86% ownership [2]. - The former employee, David, alleges that Huaxi Xinyu concealed the holding of 30 million shares of Jinzhou Bank and committed fraud in bond issuance, as well as inflating revenue figures [1][2]. - Significant discrepancies were noted in financial reports, with 2017's first half revenue reported at 2.78 billion yuan, a dramatic increase from 25 million yuan in 2016, while the annual report showed a return to only 303 million yuan [5][12]. Stock Performance - As of August 7, Huaxi Biological's stock price was 52.19 yuan per share, down over 80% from its peak of 299 yuan in July 2021 [3]. Internal Conflicts and Governance Issues - The company has faced multiple internal disputes, including a recent incident involving a former employee's allegations of workplace bullying and financial misconduct [20][21]. - The company has been under scrutiny for its governance practices, reflecting a broader trust crisis within the organization [22]. Regulatory Scrutiny - The China Securities Regulatory Commission issued a warning to Huaxi Xinyu regarding inaccurate cost disclosures in bond issuance documents, stemming from the allegations made by the former employee [18]. - Previous investigations into the company during its IPO process found no evidence of fraud, despite the ongoing allegations [17]. Historical Context - The former employee claims to have reported financial irregularities to regulatory bodies in 2019, which led to investigations that ultimately cleared the company of wrongdoing at that time [17][18].